Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00440388. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Phase II Study of AT-101 in Combination With Rituximab in Patients With Untreated, Grade I-II, Follicular Non-Hodgkin's Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase II clinical trial in patients who have not received systemic treatment for follicular non-Hodgkin's lymphoma. The study combines rituximab, an approved drug for this disease, with AT-101, an experimental drug. The hypothesis is that by adding AT-101 to the rituximab regimen, improvement to patients' response to the treatment will be observed verses rituximab alone.
Study identification
- NCT ID
- NCT00440388
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2006 (Type not available)
- Primary completion
- Nov 2008 (Actual)
- Completion
- Nov 2008 (Actual)
- Last update posted
- Aug 27, 2010
2006 – 2008
United States locations
- U.S. sites
- 28
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35296 | — |
| Hematology Oncology Associates | Phoenix | Arizona | — | — |
| Rocky Mountain Cancer Center-Aurora | Aurora | Colorado | — | — |
| Florida Cancer Institute | Hudson | Florida | 34667 | — |
| Florida Cancer Institute | New Port Richey | Florida | 34655 | — |
| Cancer Care & Hematology Specialists of Chicagoland | Arlington Heights | Illinois | — | — |
| Central Indiana Cancer Centers | Fishers | Indiana | — | — |
| University of Michigan Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Minnesota Oncology Hematology, P.A. | Minneapolis | Minnesota | — | — |
| Missouri Cancer Associates | Columbia | Missouri | — | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | — | — |
| Hematology/Oncology Associates | Albuquerque | New Mexico | 87106 | — |
| New York Oncology Hematology, P.C. | Albany | New York | — | — |
| Duke University Medical Center | Durham | North Carolina | 27707 | — |
| Northwest Cancer Specialists | Portland | Oregon | — | — |
| The Jones Clinic | Germantown | Tennessee | 38138 | — |
| Texas Oncology, P.A. | Bedford | Texas | — | — |
| Texas Cancer Center at Medical City | Dallas | Texas | — | — |
| Texas Oncology, P.A. | Fort Worth | Texas | — | — |
| Allison Cancer Center | Midland | Texas | — | — |
| HOAST - New Braunfels | New Braunfels | Texas | — | — |
| West Texas Cancer Center | Odessa | Texas | — | — |
| Hematology Oncology Physicians of Texas | Richardson | Texas | 75080 | — |
| Tyler Cancer Center | Tyler | Texas | — | — |
| Virginia Oncology Associates | Chesapeake | Virginia | — | — |
| Oncology and Hematology Associates of SW Virginia, Inc. | Salem | Virginia | 24153 | — |
| Cancer Care Northwest | Spokane | Washington | 99202 | — |
| St. Mary's Medical Center | Huntington | West Virginia | 25701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00440388, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2010 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00440388 live on ClinicalTrials.gov.